



10/635946

c o f c

Practitioner's Docket No.: PH 7167 Div 1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. PATENT: 6,984,651

PATENTEE: John V. Duncia, et. al.

ISSUED: Jan. 10, 2006

ASSIGNEE: Bristol Myers Squibb Pharma Company

TITLE: PIPERDINE AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR
ACTIVITY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attention: Decision and Certification Branch of Patent Issue Division

Certificate
JUL 05 2006
of Correction

Sir:

REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT
PURSUANT TO 37 C.F.R §1.322

The patentees through their agent hereby respectfully request that a certificate of correction be issued to correct printing errors in accordance with the attached Certificate of Correction Form 1050, submitted in duplicate, herewith.

Pursuant to 37 C.F.R §1.322, patentees request that a certificate of correction enclosed herewith be issued for mistakes by the Patent and Trademark Office. The mistakes made by the Patent and Trademark Office are tabulated in Table 1.

Support for the requested corrections can be found in the application. The requested corrections for mistakes by patentees are clerical or typographical in nature and do not involve such changes in the patent as would constitute new matter or would require re-examination.

JUL 06 2006

Table 1 : Mistakes made by the Patent and Trademark Office


– U.S. Patent 6,984,651

Corrections requested in the patent:	Errors shown correctly in Applicant's Amendment of 11/30/2004 or Application:
On title page, Related U.S. Application Data, delete "Division of application No. 09/885,550, filed on June 29, 2001," and insert – Division of application No. 09/885,550, filed on June 20, 2001, --	
In column 200, line 5, delete the " $(CH_2)_n C(O)NR^{13a}R^{13a'}$," and insert -- $(CH_2)_w C(O)NR^{13a}R^{13a'}$, --	Amendment, page 24.
In column 200, line 6, delete the " $(CH_2)_n S(O)_2 NR^{13a}R^{13a'}$," and insert -- $(CH_2)_w S(O)_2 NR^{13a}R^{13a'}$, --	Amendment, page 24.
In column 202, lines 42-43, delete the "bullous pemphigoid, allergic eczema, conjunctivitis," and insert – bullous pemphigoid, allergic collitis, eczema, conjunctivitis, --	Amendment, page 31.

Please send the Certificate to:

Mary K. VanAtten
Bristol-Myers Squibb Pharma Company
c/o Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Bristol-Myers Squibb Pharma Company
(Assignee)


(Person authorized to sign on behalf of assignee)
Mary K. VanAtten
Patent Attorney

JUL 06 2006

Assignment on the above patent was recorded on 01/15/02, and can be found on Reel 012479, Frame 0627 to Assignee, Bristol-Myers Squibb Pharma Company.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Mary VanAtten", with a stylized flourish at the end.

Mary K. VanAtten
Attorney for Patentees
Registration No. 39,408
Telephone: 609-252-4379

Attachment (Form 1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,984,651

DATED : Jan. 10, 2006

INVENTOR(S) : John V. Duncia, et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page:

Related U.S. Application Data, delete "Division of application No. 09/885,550, filed on June 29, 2001," and insert -- Division of application No. 09/885,550, filed on June 20, 2001, --;

Column 200:

Line 5, delete the " $(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^{13a}\text{R}^{13a'}$," and insert -- $(\text{CH}_2)_w\text{C}(\text{O})\text{NR}^{13a}\text{R}^{13a'}$, --;

Line 6, delete the " $(\text{CH}_2)_n\text{S}(\text{O})_2\text{NR}^{13a}\text{R}^{13a'}$," and insert -- $(\text{CH}_2)_w\text{S}(\text{O})_2\text{NR}^{13a}\text{R}^{13a'}$, --;

Column 202:

Lines 42-43, delete the "bullous pemphigoid, allergic eczema, conjunctivitis," and insert -- bullous pemphigoid, allergic collitis, eczema, conjunctivitis, --.

Certificate of Correction (PTO Form 1050) (reproduced)

PATENT NO.: 6,984,651

MAILING ADDRESS OF SENDER:
Mary K. VanAtten
Bristol-Myers Squibb Pharma Company
c/o Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

JUL 06 2006

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,984,651

DATED : Jan. 10, 2006

INVENTOR(S) : John V. Duncia, et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page:

Related U.S. Application Data, delete "Division of application No. 09/885,550, filed on June 29, 2001," and insert -- Division of application No. 09/885,550, filed on June 20, 2001, --;

Column 200:

Line 5, delete the " $(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^{13a}\text{R}^{13a'}$," and insert -- $(\text{CH}_2)_w\text{C}(\text{O})\text{NR}^{13a}\text{R}^{13a'}$, --;

Line 6, delete the " $(\text{CH}_2)_n\text{S}(\text{O})_2\text{NR}^{13a}\text{R}^{13a'}$," and insert -- $(\text{CH}_2)_w\text{S}(\text{O})_2\text{NR}^{13a}\text{R}^{13a'}$, --;

Column 202:

Lines 42-43, delete the "bullous pemphigoid, allergic eczema, conjunctivitis," and insert -- bullous pemphigoid, allergic collitis, eczema, conjunctivitis, --.


Certificate of Correction (PTO Form 1050) (reproduced)

PATENT NO.: 6,984,651

MAILING ADDRESS OF SENDER:

Mary K. VanAtten
Bristol-Myers Squibb Pharma Company
c/o Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

JUL 06 2006



Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on June 27, 2006
Date

Mary VanAtten
Signature

Mary K. VanAtten
Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

PH7167 DIV [1]
Request for Certificate of Correction
PTO 1050 Form

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JUL 06 2006